Meloxicam is an NSAID used to treat osteoarthritis in adults, rheumatoid arthritis in adults, and juvenile rheumatoid arthritis in pediatrics. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing.
- Mechanism
- Curator reviewed · 3 references
Meloxicam inhibits prostaglandin synthetase (cylooxygenase 1 and 2) enzymes leading to a decreased synthesis of prostaglandins, which normally mediate painful inflammatory symptoms. As prostaglandins sensitize neuronal pain receptors, inhibition of their synthesis leads to analgesic and inflammatory effects. Meloxicam preferentially inhibits COX-2, but also exerts some activity against COX-1, causing gastrointestinal irritation.
- Primary indication
- Meloxicam on its own is indicated for: the symptomatic treatment of arthritis and osteoarthritis. - the pauciarticular and polyarticular course of Juvenile Rheumatoid Arthritis (JRA) in patients aged 2 years old or above. - the...Curator reviewed · 16 structured indications
- Formula / weight
- C14H13N3O4S2 · 351.401 g/mol (avg)
- First approval
- Canada, 2000 · United States, 2000
- Code names
- N-1539 · UH-AC62 · UH-AC 62XX
- Brand names
Resolves to
ZRVUJXDFFKFLMG-UHFFFAOYSA-NSMILESCN1C(C(=O)NC2=NC=C(C)S2)=C(O)C2=C(C=CC=C2)S1(=O)=OWhat you can answer from here — as of September 20, 2026
Which drugs share a target with Meloxicam, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account